Yagita M, Ieki Y, Onishi R, Huang C L, Adachi M, Horiike S, Konaka Y, Taki T, Miyake M
Department of Clinical Hematology and Immunology, Tazuke-Kofukai Medical Research Institute, Kitano Hospital, Kita-ku, Osaka 530-0026, Japan.
Int J Oncol. 1998 Jul;13(1):91-6. doi: 10.3892/ijo.13.1.91.
We report a high risk of therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) in patients receiving oral administration of etoposide for recurrent breast cancer. We examined 119 patients with recurrent disease. Patients were initially treated with anthracyclines, cyclophosphamide, or cisplatin with or without radiation before etoposide treatment. Etoposide was used as the final drug in most cases. Twenty-four patients were treated with the oral administration of etoposide (50 or 100 mg/day for 5-7 days at 4-week intervals). Three cases of t-AML/MDS developed among those 24 patients exposed to etoposide. In contrast, the development of t-AML/MDS was not observed in the other 95 patients not treated with etoposide. Our data suggest that there is a substantial risk of secondary leukemia with oral administration of etoposide for a prolonged period as well as i.v. schedules.
我们报告了口服依托泊苷用于复发性乳腺癌患者时发生治疗相关急性髓系白血病和骨髓增生异常综合征（t-AML/MDS）的高风险。我们研究了119例复发性疾病患者。患者在接受依托泊苷治疗前，最初接受了蒽环类药物、环磷酰胺或顺铂治疗，部分患者还接受了放疗。在大多数情况下，依托泊苷用作最后一种药物。24例患者接受了口服依托泊苷治疗（50或100毫克/天，持续5-7天，每4周为一个周期）。在这24例接受依托泊苷治疗的患者中，有3例发生了t-AML/MDS。相比之下，在未接受依托泊苷治疗的其他95例患者中未观察到t-AML/MDS的发生。我们的数据表明，长期口服依托泊苷以及静脉给药方案均存在继发白血病的重大风险。
